Initial Triple Combination Therapy for Intermediate-and High-Risk Pulmonary Arterial Hypertension: Standard of Care or Still Too Soon to Tell?
作者信息
Jin Qi, Guan Lihua, Pan Wenzhi, Zhou Daxin
机构信息
Zhongshan Hospital, Fudan University Shanghai, China.
出版信息
Am J Respir Crit Care Med. 2021 Dec 15;204(12):1491-1492. doi: 10.1164/rccm.202107-1622LE.
Abstract
摘要
相似文献
1
Initial Triple Combination Therapy for Intermediate-and High-Risk Pulmonary Arterial Hypertension: Standard of Care or Still Too Soon to Tell?中高危肺动脉高压的初始三联联合治疗：是治疗标准还是仍有待观察？
Am J Respir Crit Care Med. 2021 Dec 15;204(12):1491-1492. doi: 10.1164/rccm.202107-1622LE.
2
COUNTERPOINT: Should Initial Combination Therapy Be the Standard of Care in Pulmonary Arterial Hypertension? No.反方观点：初始联合治疗应成为肺动脉高压的标准治疗方案吗？不应如此。
Chest. 2019 Dec;156(6):1043-1045. doi: 10.1016/j.chest.2019.07.004.
3
Counterpoint: Should the Use of Upfront Triple Combination Therapy Be Standard of Care in Pulmonary Arterial Hypertension? No.反对观点：初始三联联合疗法应成为肺动脉高压的标准治疗方案吗？不应该。
Chest. 2024 Mar;165(3):494-496. doi: 10.1016/j.chest.2023.07.4229.
4
POINT: Should the Use of Upfront Triple Combination Therapy Be Standard of Care in Pulmonary Arterial Hypertension? Yes.观点：初始三联联合疗法应成为肺动脉高压的标准治疗方案吗？ 应该。
Chest. 2024 Mar;165(3):492-494. doi: 10.1016/j.chest.2023.10.001.
5
Initial triple therapy in pulmonary arterial hypertension: coming of age and rejuvenated.肺动脉高压的初始三联疗法：走向成熟与焕发生机
Eur Respir J. 2021 Jan 28;57(1). doi: 10.1183/13993003.04258-2020. Print 2021 Jan.
6
Rebuttal From Drs Channick and Saggar.
Chest. 2019 Dec;156(6):1047-1048. doi: 10.1016/j.chest.2019.07.006.
7
Rebuttal From Drs Humbert and Lau.
Chest. 2019 Dec;156(6):1045-1046. doi: 10.1016/j.chest.2019.07.003.
8
[Pulmonary arterial hypertension: achievements and realities of modern treatment, a look into the future].[肺动脉高压：现代治疗的成就与现状，展望未来]
Ter Arkh. 2021 Sep 15;93(9):1009-1017. doi: 10.26442/00403660.2021.09.201013.
9
Upfront Combination Therapy: Growing the Case to Get Ahead of Pediatric Pulmonary Arterial Hypertension.初始联合治疗：拓展小儿肺动脉高压治疗的领先优势
Ann Am Thorac Soc. 2022 Feb;19(2):163-165. doi: 10.1513/AnnalsATS.202108-975ED.
10
Continued Progress in Therapy for Pulmonary Arterial Hypertension.肺动脉高压治疗的持续进展。
N Engl J Med. 2023 Apr 20;388(16):1524-1526. doi: 10.1056/NEJMe2300324. Epub 2023 Mar 6.
本文引用的文献
1
Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension.初始治疗策略与肺动脉高压长期生存的关系。
Am J Respir Crit Care Med. 2021 Oct 1;204(7):842-854. doi: 10.1164/rccm.202009-3698OC.
2
Risk stratification and medical therapy of pulmonary arterial hypertension.肺动脉高压的风险分层与药物治疗。
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01889-2018. Print 2019 Jan.
3
Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study.西地那非联合他达拉非治疗勃起功能障碍的临床疗效和安全性
Am J Cardiovasc Drugs. 2018 Feb;18(1):37-47. doi: 10.1007/s40256-017-0262-z.
4
Beyond a single pathway: combination therapy in pulmonary arterial hypertension.超越单一途径：肺动脉高压的联合治疗
Eur Respir Rev. 2016 Dec;25(142):408-417. doi: 10.1183/16000617.0085-2016.
5
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).2015 ESC/ERS 肺动脉高压诊断与治疗指南：欧洲心脏病学会（ESC）和欧洲呼吸学会（ERS）肺动脉高压诊断与治疗工作组制定：该指南得到了欧洲儿科和先天性心脏病协会（AEPC）以及国际心肺移植学会（ISHLT）的认可。
Eur Respir J. 2015 Oct;46(4):903-75. doi: 10.1183/13993003.01032-2015. Epub 2015 Aug 29.
6
Treatment of idiopathic/hereditary pulmonary arterial hypertension.特发性/遗传性肺动脉高压的治疗
J Cardiol. 2014 Oct;64(4):243-9. doi: 10.1016/j.jjcc.2014.06.009. Epub 2014 Jul 28.
Zotero 插件